BY 27

BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.

BPO-27 racemate (BPO-27 (racemate)) is an effective CFTR inhibitor with IC50 of 8 nM.

HS-27 is a fluorescently-tethered inhibitor of Hsp90 with SNX-5422 tethered via a PEG linker to a fluorescein isothiocyanate or FITC. HS-27 can be used in see-and-treat paradigms.

SM27 is a fibroblast growth factor 2 (FGF2) inhibitor with anti-angiogenic activity and can be used to study tumours.

BAY-27-9955 is a glucagon receptor antagonist.

Anti-Human IFN gamma Antibody (B27) is a monoclonal antibody targeting human IFN‑γ and can be used in immunological research.

4E1rcat 27d (Compound 27d) contains a core structure of (E)-3-(2-furanylmethylene)-2-pyrrolidinone. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

ATG5-PPI Inhibitor 27e has a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC₅₀ values of >33 μM and 17.26 μM, respectively.

ATG5-PPI Inhibitor 27g has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure and blocks the interactions between ATG5‑ATG16L1 and ATG5‑TECAIR in in vitro binding assays, with IC50 values of 25 μM and 16 μM, respectively.

ATG5-PPI Inhibitor 27a has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidone and blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 2.29 μM and 3.68 μM, respectively.

high affinity agonist of the translocator protein

β-Endorphin (1-27) (human) acetate, existing in the hypophysis cerebri and hypothalamus, exhibits antinociception activity. β-Endorphin (1-27) (human) acetate is an agonist of opioid receptor, showing preferred affinity for μ-opioid receptor and δ-opioid

BRD4 Inhibitor-27 is a potent BRD4 inhibitor that inhibits BRD4 BD1 and BRD4 BD2 with IC50s of 9.6 and 11.3 μM, respectively.BRD4 Inhibitor-27 has anticancer activity and can be used for breast cancer research.

AChE-IN-27 is a small molecule used for high-throughput assays.

FLT3-IN-27 (compound 49) is an inhibitor of FLT3-ITD with an IC50 of 174 nM. It impedes cell growth by causing cell cycle arrest at the G1 phase, making it suitable for research in acute myeloid leukemia.

HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active, HDACI class-selective inhibitor, with IC50 values ranging from 0.43 to 3.01 nM for HDAC1-3. This compound exhibits both in vivo and in vitro anticancer activity. HDAC-IN-27 shows significant antiproliferative effects against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). It is useful for research on acute myeloid leukemia (AML).

AKT-IN-27 (4a) is a potential anticancer drug that functions by selectively targeting Akt-driven signaling pathways. It induces apoptosis by activating caspase-3, causing G2/M phase cell cycle arrest, and disrupting mitochondrial membrane potential. AKT-IN-27 (4a) is applicable in research on triple-negative breast cancer (TNBC).

ATX inhibitor 27 (Compound 31) is an ATX inhibitor. It demonstrates IC50 values of 13 nM against human autotaxin (hATX) and 23 nM against lysophosphatidylcholine (LPC). By inhibiting the ATX enzyme, ATX inhibitor 27 reduces LPA levels in the body. This compound is applicable in research related to ATX-LPA-associated conditions such as inflammation, neurodegenerative disorders, and cancer.

MDM2-IN-27 primarily targets the MDM2 protein with a Ki value of 0.4 nM. By blocking the negative regulation of p53 by MDM2, it activates the tumor-suppressing activity of p53 and induces apoptosis.

SDH-IN-27 (Compound Q18) is a succinate dehydrogenase inhibitor (SDHI) with an IC50 of 9.7 mg/L. It induces hyphal morphological changes and lipid peroxidation, demonstrating antifungal activity against C. camelliae with an EC50 of 6.0 mg/L. SDH-IN-27 also acts as an ergosterol biosynthesis inhibitor (EBI) by binding to the active site of CYP51, ultimately resulting in the death of pathogenic fungal cells.

AChE/BChE-IN-27 is a brain-permeable dual inhibitor of AChE and BChE, with IC50 values of 3.72 μM and 9.65 μM, respectively, and a permeability coefficient (Pe) of 4.12. It exhibits significant antioxidant activity with an IC50 of 6.32 μM in DPPH assays and also demonstrates strong in vitro antioxidant capabilities. The compound shows metal-chelating properties and has neuroprotective potential against oxidative stress by significantly reducing intracellular reactive oxygen species (ROS). In vivo experiments reveal that AChE/BChE-IN-27 effectively restores AChE and BChE levels and improves cognitive function, indicating its potential application for Alzheimer’s disease (AD).

IDO1-IN-27 (Compound I-1) is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), displaying an IC50 of 0.3951 μM against recombinant hIDO1. It also inhibits hIDO1 expression in HeLa cells with an EC50 of 62 nM. By reducing the mRNA expression of pro-inflammatory factors (TNF-α, IL-6, and IL-1β), IDO1-IN-27 effectively stimulates T cell proliferation and simultaneously inhibits the growth of LLC cells.

27-Hydroxy oncosterone is a metabolite that inhibits the proliferation of breast cancer (BC) cells, and it also prevents the proliferation of BC cells induced by cancerosterone and 27-Hydroxycholesterol.

CYP51-IN-27 is an inhibitor of sterol 14α-demethylase CYP51 with an IC50 of 0.3434 μg/mL. It exhibits antifungal activity by inhibiting the production of fungal ergosterol. CYP51-IN-27 is applicable in infection-related research, such as studies on rice sheath blight.